Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma

Glioblastoma (GBM) is highly aggressive and has a poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, and the potential to enhance chemoradiation. The purpose of this clinical trial was to assess the efficacy of combining belinostat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Karen Xu, Karthik Ramesh, Vicki Huang, Saumya S. Gurbani, James Scott Cordova, Eduard Schreibmann, Brent D. Weinberg, Soma Sengupta, Alfredo D. Voloschin, Matthias Holdhoff, Peter B. Barker, Lawrence R. Kleinberg, Jeffrey J. Olson, Hui-Kuo G. Shu, Hyunsuk Shim
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI AG 2022-03-01
Cyfres:Tomography
Pynciau:
glioblastoma
histone deacetylase
epigenetic drug
radiation sensitizer
magnetic resonance spectroscopy
Mynediad Ar-lein:https://www.mdpi.com/2379-139X/8/2/57
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg